Albert David valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
19.53×————
1.13×————
1.21×————
Enterprise multiples
0.67×————
9.11×————
14.26×————
Yield
5.1%————
−1.7%————
Reference — adjusted share basis
₹772.00————
₹39.54−₹2.62₹30.14₹132.15₹63.38
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ALBERTDAVD₹772.00

Albert David Limited

· Pharma & Health
₹ CrorePeersVALIANTLABHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURYMcap ₹441 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————19.53
P/B————1.13
P/Sales————1.21
Enterprise Multiples
EV/Sales————0.67
EV/EBITDA————9.11
EV/EBIT————14.26
Yield
Earnings Yield %————5.12
FCF Yield %————-1.74
Reference — adjusted share basis
Price (FY-end close, adj.)————772.00
EPS (adj.)63.38132.1530.14-2.6239.54
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.